1. Valuation Methodology and Defensibility
The three primary approaches to valuing IP and technology are the income method, the market method, and the cost method. The income method projects future cash flows attributable to the asset and discounts them to present value. This approach is often the most defensible for revenue-generating IP, but it requires credible assumptions about market penetration, customer retention, and competitive dynamics. The market method looks to comparable licenses or sales of similar technology; it is appealing in concept, but it is frequently limited by the scarcity of true comparables and the confidential nature of most licensing deals. The cost method sums the costs incurred to develop or acquire the asset, adjusted for obsolescence; this approach is generally the least reliable for valuation, but it may serve as a floor or sanity check.
In practice, courts and appraisers rarely rely on a single method. A defensible valuation typically triangulates across two or all three approaches and reconciles the results, disclosing the weight given to each. From a practitioner's perspective, the methodology selected at the outset often determines whether the valuation will survive challenge in litigation or regulatory review. The choice of method should reflect both the nature of the asset and the specific legal or business context in which the valuation is being performed.
Income Method and Cash Flow Attribution
The income method requires forecasting the revenue streams generated by the IP or technology over its remaining useful life. This is where disputes most frequently arise. A licensor and licensee may agree that a software platform generates $10 million in annual revenue, but they may sharply disagree on what portion of that revenue is attributable to the licensed IP versus complementary assets such as customer relationships, brand, or operational know-how. Courts have developed various frameworks to isolate the IP contribution, including the profit-split method, the relief-from-royalty method, and the incremental income method. The relief-from-royalty approach, for example, calculates what a hypothetical licensee would pay to avoid infringing the IP. This requires estimating a reasonable royalty rate for similar technology, which itself is often contentious.
Discount rate selection compounds the uncertainty. The rate applied to future cash flows reflects the risk that the projected revenues will not materialize. A higher discount rate depresses valuation; a lower rate inflates it. Valuation experts often disagree sharply on what discount rate is appropriate for early-stage technology, software with uncertain market adoption, or patents in crowded fields where design-around alternatives may emerge. This is where asset valuation expertise becomes critical. Counsel must evaluate whether the discount rate reflects genuine market risk or embeds assumptions that bias the result.
Market Method and Comparable Licensing Data
The market method seeks to identify arm's-length license agreements or asset sales involving comparable IP. When such comparables exist, they anchor the valuation and lend credibility to the result. However, comparables are often elusive. Most licensing deals include confidentiality provisions that prevent disclosure. The technology landscape shifts rapidly; a license signed three years ago may not reflect current market conditions. And true comparability is rare: one patent portfolio may cover a narrow technical field with limited commercial application, while another may span multiple industries and revenue streams.
Valuation experts sometimes construct synthetic comparables by adjusting known deals for differences in scope, geography, and market conditions. In my view, this approach has surface-level transparency, but it remains inherently speculative when adjustments are large or underlying data are dated. Courts view it skeptically when the adjustments are large or the underlying comparables are dated. In biotechnology and pharmaceutical contexts, where licensing is more common and data more available, the market method carries greater weight. For early-stage software or emerging technologies, comparables may simply not exist, and the valuation must rest on income projections or cost-plus methodologies.
2. Regulatory and Tax Implications
IP valuation is not merely an appraisal exercise; it carries direct tax and regulatory consequences. In M&A transactions, the purchase price allocation determines how much of the acquisition cost is assigned to intangible assets versus tangible assets and goodwill, which directly affects depreciation deductions and future tax liability. The IRS scrutinizes these allocations closely, particularly when they seem designed to maximize tax deductions or minimize reported income. Transfer pricing regulations require that intercompany licensing fees reflect an arm's-length rate; companies that underprice internal technology transfers face IRS challenges and penalties.
In litigation involving damages for patent infringement or trade secret misappropriation, the valuation of the IP directly determines the damages award. A defendant's infringement exposure can swing from millions to tens of millions based on which valuation methodology the jury finds persuasive. Bankruptcy and insolvency proceedings also hinge on IP valuation: creditors' recovery often depends on how much value can be extracted from the debtor's technology assets, and the valuation affects the feasibility of a reorganization plan. Counsel must ensure that the valuation methodology chosen is defensible not only in the immediate context but also if challenged by a tax authority, opposing party, or court.
New York Court Treatment of Technology Valuations
New York courts, particularly the Commercial Division of the Supreme Court and the federal courts in the Southern District of New York, have developed a substantial body of case law on IP valuation in commercial disputes. These courts generally require that valuation experts base their opinions on reliable methodologies, transparent assumptions, and comparables or market data where available. Daubert-style challenges to expert testimony on valuation are common, and courts will exclude opinions that rest on speculative cash flow projections or fail to account for market risk. New York courts also recognize that valuation is often a matter of judgment rather than scientific precision, and they may award damages based on a range of reasonable valuations rather than a single point estimate.
3. Practical Risk Areas and Strategic Timing
Several practical issues frequently create valuation disputes. First, the definition of the asset being valued must be precise. Is the valuation for a single patent, a patent portfolio, the underlying technology, or the entire business unit that exploits the technology? Ambiguity here leads to disputes about scope and comparability. Second, the useful life of the asset must be realistic. Patents expire; technology becomes obsolete; and market conditions shift. A valuation that assumes the technology will generate revenue for twenty years when the patent expires in five years will not withstand scrutiny.
Third, the treatment of contingencies and milestone events affects valuation materially. If the technology's commercial viability depends on regulatory approval or customer adoption, the valuation must reflect the probability and timing of those events. Overestimating the likelihood of success inflates value; underestimating it may understate legitimate asset worth. Fourth, the choice of valuation date is critical. In litigation, the valuation date is often fixed by statute or court order; in M&A, the choice of valuation date can affect the allocation of risk between buyer and seller.
Documentation and Expert Engagement
Counsel should engage valuation experts early and ensure that the scope of work is clearly defined. The expert should document all assumptions, sources of data, and the reasoning behind methodological choices. In litigation, this documentation becomes critical if the expert is deposed or required to testify. In transactions, clear documentation protects both parties by establishing that the valuation was performed in good faith using reasonable methodology. Consider also whether the valuation will be subject to tax authority challenge or regulatory review; if so, the expert should be selected with that context in mind, and the methodology should emphasize defensibility and comparability to market standards.
The interaction between IP valuation and biotech patent strategy is particularly nuanced. In biotechnology, patent strength, remaining exclusivity, and clinical trial outcomes all influence valuation significantly. A valuation performed before clinical trial results are known will differ substantially from one performed after approval or failure. Counsel must coordinate with technical experts and business stakeholders to ensure that the valuation reflects the current state of development and the realistic probability of commercialization.
4. Forward-Looking Considerations
As you evaluate IP and technology valuation in your own context, consider whether the methodology chosen aligns with how courts and regulators in your jurisdiction have treated similar assets. Assess whether the underlying assumptions about market conditions, useful life, and competitive risk are grounded in current data or rest on outdated comparables. Determine whether the expert selected has experience with your specific technology domain and with the legal or regulatory context in which the valuation will be used. Finally, build in flexibility: valuations are snapshots in time, and as market conditions, competitive dynamics, or regulatory status change, the valuation may need revision. Early coordination between counsel, finance, and technical experts ensures that the valuation serves its intended purpose and withstands challenge.
| Valuation Method | Primary Strength | Primary Limitation |
| Income Method | Reflects revenue-generating potential directly | Requires credible cash flow projections; sensitive to discount rate |
| Market Method | Anchored to observable arm's-length transactions | Comparables often scarce, confidential, or dated |
| Cost Method | Objective, based on historical spend | Does not reflect market value or competitive dynamics |
02 Apr, 2026
